Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Morgenstern

Showing results (81-90 of 179) with videos related to

Pageof 18
Sort By:
Cancer Research|January 20, 2011
Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)Damian Wild, Michael Frischknecht, Hanwen Zhang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 25, 2007
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancerSebastian Knör, Sumito Sato, Timo Huber, et al.
The Journal of Infectious Diseases|April 19, 2006
Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infectionEkaterina Dadachova, Ruth A Bryan, Christos Apostolidis, et al.
Frontiers in Medicine|January 7, 2016
Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal CarcinomatosisAurélie Derrien, Sébastien Gouard, Catherine Maurel, et al.
Molecules (Basel, Switzerland)|February 29, 2020
Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with <sup>225</sup>Ac as a Perspective Tool for Combined α-Radioimmunotherapy and Magnetic Hyperthermia of HER2-Positive Breast CancerEdyta Cędrowska, Marek Pruszyński, Weronika Gawęda, et al.
EJNMMI Research|April 26, 2017
Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the <sup>213</sup>Bi-labeled monoclonal antibody MX35 in an ovarian cancer modelAnna Gustafsson-Lutz, Tom Bäck, Emma Aneheim, et al.
EJNMMI Radiopharmacy and Chemistry|June 30, 2023
First preclinical evaluation of [<sup>225</sup>Ac]Ac-DOTA-JR11 and comparison with [<sup>177</sup>Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETsMaryana Handula, Savanne Beekman, Mark Konijnenberg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 27, 2019
Correction to: <sup>225</sup>Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot studyMike Sathekge, Frank Bruchertseifer, Otto Knoesen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 5, 2015
Utilizing High-Energy γ-Photons for High-Resolution 213Bi SPECT in MiceJan de Swart, Ho Sze Chan, Marlies C Goorden, et al.
Nuclear Medicine and Biology|January 3, 2017
Nanozeolite bioconjugates labeled with <sup>223</sup>Ra for targeted alpha therapyAgata Piotrowska, Sylwia Męczyńska-Wielgosz, Agnieszka Majkowska-Pilip, et al.
Pageof 18

Showing results (81-90 of 179) with videos related to

Sort By:
Pageof 18
Cancer Research|January 20, 2011
Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)Damian Wild, Michael Frischknecht, Hanwen Zhang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 25, 2007
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancerSebastian Knör, Sumito Sato, Timo Huber, et al.
The Journal of Infectious Diseases|April 19, 2006
Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infectionEkaterina Dadachova, Ruth A Bryan, Christos Apostolidis, et al.
Frontiers in Medicine|January 7, 2016
Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal CarcinomatosisAurélie Derrien, Sébastien Gouard, Catherine Maurel, et al.
Molecules (Basel, Switzerland)|February 29, 2020
Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with <sup>225</sup>Ac as a Perspective Tool for Combined α-Radioimmunotherapy and Magnetic Hyperthermia of HER2-Positive Breast CancerEdyta Cędrowska, Marek Pruszyński, Weronika Gawęda, et al.
EJNMMI Research|April 26, 2017
Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the <sup>213</sup>Bi-labeled monoclonal antibody MX35 in an ovarian cancer modelAnna Gustafsson-Lutz, Tom Bäck, Emma Aneheim, et al.
EJNMMI Radiopharmacy and Chemistry|June 30, 2023
First preclinical evaluation of [<sup>225</sup>Ac]Ac-DOTA-JR11 and comparison with [<sup>177</sup>Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETsMaryana Handula, Savanne Beekman, Mark Konijnenberg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 27, 2019
Correction to: <sup>225</sup>Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot studyMike Sathekge, Frank Bruchertseifer, Otto Knoesen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 5, 2015
Utilizing High-Energy γ-Photons for High-Resolution 213Bi SPECT in MiceJan de Swart, Ho Sze Chan, Marlies C Goorden, et al.
Nuclear Medicine and Biology|January 3, 2017
Nanozeolite bioconjugates labeled with <sup>223</sup>Ra for targeted alpha therapyAgata Piotrowska, Sylwia Męczyńska-Wielgosz, Agnieszka Majkowska-Pilip, et al.
Pageof 18